Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Akari Therapeutics Plc's Competitiveness

Name: Akari Therapeutics Plc Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Akari Therapeutics Plc (AKTX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q1 2026

Competitors

Named by the company

Peer Group Market Share

Share of combined sales, Q1 2026

Revenue Growth Y/Y

Peers: 8.16 %

Net Margin

Peers: 12.97 %

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/AKTX/competitors

https://api.csimarket.com/api/v1/companies/AKTX/relationships

https://api.csimarket.com/api/v1/companies/AKTX/similar

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Business Relationships API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AI Integration via MCP

Connect Claude, ChatGPT, or any MCP-compatible AI assistant directly to this data.

Akari Therapeutics Plc's Competitor Quality Breadth

Group definitions: see Methodology: Performance Group Definitions.

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Akari Therapeutics Plc	-	-	-	No
Competitors combined (36)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

AKTX Stock Performance relative to its Competitors

AKTX Competitors (weighted) Percent change over the selected range

Akari Therapeutics Plc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

Competitors Combined
(13 of 32)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Akari Therapeutics Plc	-71.50 %	Underperformed
Competitors combined (32)	40.4%	63.2%
High-Confidence Competitors (0)	40.4%	63.2%
Similar-Size Competitors (0)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Akari Therapeutics Plc's competitor groups requires a Commercial License.

Unlock Full Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

5 Best-Performing Tracked Competitors, Trailing 12 Months

#	Competitor	TTM Share Price Return	vs U.S.A. 500
1	Prelude Therapeutics Inc	282.9%	Outperformed
2	Immunovant Inc	282.9%	Outperformed
3	Viatris Inc	282.9%	Outperformed
4	Greenwich Lifesciences Inc	282.9%	Outperformed
5	Teva Pharmaceutical Industries Limited	282.9%	Outperformed

Best-Performing Competitor Returns

TTM share price return and U.S.A. 500 outperformance for Akari Therapeutics Plc's best-performing competitors requires a Commercial License.

Unlock Full Access

Source: CSIMarket API, trailing 12 months.

Akari Therapeutics Plc's Comment on Competition and Industry Peers

The company operates in the biotechnology and pharmaceutical industries, focusing on the oncology subsector. This sector is characterized by rapid technological change, intense competition, and strong protection of intellectual property. The company competes with larger, better-funded biotechnology and pharmaceutical firms, academic institutions, governmental agencies, and both public and private research organizations. It also faces competition from smaller or early-stage companies, universities, and other research institutions developing cancer therapeutics. Its product candidates may compete with existing and emerging therapies, including surgery, radiation, chemotherapy, hormone therapy, biologic therapies such as monoclonal and bispecific antibodies, immunotherapy, cell-based therapy, and targeted therapy. Competition extends across the oncology market for cost-effective and reimbursable cancer treatments. Market acceptance and achieving significant market share may be challenging due to competition and preferences by insurers or reimbursement authorities for generic or specific branded products. Bayer Pharmaceuticals is identified as a competitor in the company's filings.

Publicly Traded Peers of Akari Therapeutics Plc

Revenue and income for trailing 12 months, in millions of $, except employees

Company	Market Cap	Revenues	Income	Employees
Akari Therapeutics Plc	884,739.75	-	-28.05	6
Abbvie Inc	522,704.56	66,014.00	10,346.00	57,000
Amgen Inc	255,588.06	38,903.00	9,391.00	13,000
Bristol myers Squibb Company	129,154.23	50,033.00	9,241.00	32,500
Regeneron Pharmaceuticals Inc	101,313.70	16,896.20	4,817.40	15,410
Teva Pharmaceutical Industries Limited	51,152.92	14,020.00	508.00	33,950
SUBTOTAL	2,042,000.01	210,134.78	33,025.26	199,298

31 more competitors available

Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on: November 11, 2026
Focus of this report: publicly traded companies. Ten additional tables on Akari Therapeutics Plc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.

Akari Therapeutics Plc's Competitors Named by the Company

Competitive relationships identified from Akari Therapeutics Plc reports and corroborating sources, each with a basis and confidence.

Competitor	Basis	Confidence	Active	Sources
eculizumab	Company report	85%	2022 to 2026	3

Competitor Evidence Detail

Company report basis, confidence, active dates and source counts for Akari Therapeutics Plc's named competitors require a Commercial License.

Unlock Full Access

Methodology: see Methodology: Peer & Competitor Identification, Sourcing.

Akari Therapeutics Plc's Business Segment Mix vs Peers

Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).

Company	Largest Segment	2nd Segment	3rd Segment
Amgen Inc	Reportable 100.00 %	-	-
Teva Pharmaceutical Industries Limited	United States 42.55 %	Europe 30.01 %	International Markets 13.47 %
Viatris Inc	Developed Markets 59.34 %	Greater China 18.74 %	Emerging Markets 14.16 %
Mannkind Corporation	All Other Segments 100.00 %	-	-
Journey Medical Corp	Dermatological segment 100.00 %	-	-

Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).

1 more Peers available

Akari Therapeutics Plc's Productivity vs Peers Comparison

Revenue and income per employee, trailing 12 months, in $; market cap in millions of $

Company	Market Cap	Revenue / Employee	Income / Employee
Akari Therapeutics Plc	884,740	-	-4,674,667
Abbvie Inc	522,705	1,158,140	181,509
Amgen Inc	255,588	2,992,538	722,385
Bristol myers Squibb Company	129,154	1,539,477	284,338
Regeneron Pharmaceuticals Inc	101,314	1,096,444	312,615
Teva Pharmaceutical Industries Limited	51,153	412,960	14,963
PEERS TOTAL	1,157,260	1,054,406	165,854

31 more Peers available

Akari Therapeutics Plc's Geographic Revenue Exposure vs Peers

Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.

Company	Largest Market	2nd Market	3rd Market
Bristol myers Squibb Company	United States 69.43 %	Non-US 27.48 %	Other Region 3.08 %
Teva Pharmaceutical Industries Limited	Europe 30.49 %	-	-
Beone Medicines Ltd	United States 54.39 %	China 28.38 %	Europe 12.68 %
Therapeuticsmd Inc	Non Us 66.30 %	US 33.70 %	-

Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.

Akari Therapeutics Plc's Position in Industry Market Structure

Market-capitalization share and concentration across all 491 companies in Akari Therapeutics Plc's industry classification, broader than the peer set above. Market cap in millions of $.

Akari Therapeutics Plc ranks #0 of 491 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 988, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).

Rank	Company	Market Cap	Industry Share
1	Eli Lilly And Company	1,273,174	24.00 %
2	Johnson and Johnson	679,202	12.80 %
3	Abbvie Inc	517,221	9.75 %
4	Merck and Co Inc	361,818	6.82 %
5	Novartis Ag	1,234	5.2%
6	Abbott Laboratories	1,234	5.2%
7	Novo Nordisk A	1,234	5.2%
8	Pfizer Inc	1,234	5.2%
9	Astrazeneca Plc	1,234	5.2%
10	Vertex Pharmaceuticals Inc	1,234	5.2%
0	Akari Therapeutics Plc	-	0.00 %

Full Industry Market Structure

Market cap and industry share for the rest of Akari Therapeutics Plc's industry peers requires a Commercial License.

Unlock Full Access

Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-11.

Akari Therapeutics Plc's Valuation vs Competitive Position

Valuation multiples vs the Major Pharmaceutical Preparations industry average (447 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.

Metric	Company	Industry Average	Difference
P/E	-	26.4x	-
EV / EBITDA	-	15.3x	-
P/B	48,848.9x	4.2x	+48,844.7x
Return on Equity	-123.29 %	industry aggregate	-140.10 %
Return on Invested Capital	-54.37 %	-9.41 % (avg)	-44.96 %

Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.

Akari Therapeutics Plc's Multi-Year Financial Trajectory

Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.

Metric	2019	2020	2021	2023	2024	2025
Revenue Growth	-	-	-	-	-	-
Operating Margin	-	-	-	-	-	-
Return on Invested Capital	-	-95.80 %	-91.72 %	-	-251.12 %	-29.48 %
P/E	-	-	-	-	-	-

Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.

Akari Therapeutics Plc's Competitive Forces (Porter's Five Forces)

Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.

Force	Assessment	Basis
Competitive Rivalry	High	Industry HHI of 988 (see Industry Market Structure & Concentration above)

Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Akari Therapeutics Plc's dedicated Suppliers and Customers pages, not here.

Akari Therapeutics Plc's SWOT

Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.

Strengths

No rule matched.

Weaknesses

Return on equity 140.1 points below the industry aggregate.
Underperforming the U.S.A. 500 over the trailing 12 months.

Opportunities

A meaningful share of competitors (48.60 %) show financial-distress signals, a possible opening to gain share.

Threats

Tracked peer group's revenue run-rate is broadly decelerating (-8.0% annualized).

Methodology: see Methodology: SWOT Analysis.

Akari Therapeutics Plc's Financial Strength vs Peers Comparison

Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months

Company	Quick Ratio	Working Capital	Debt / Equity	Asset Turnover
Akari Therapeutics Plc	0.23	0.26	0.04	-
Abbvie Inc	0.19	0.79	-	0.48
Amgen Inc	0.49	1.31	5.27	0.42
Bristol myers Squibb Company	0.48	1.44	2.12	0.57
Regeneron Pharmaceuticals Inc	0.58	3.56	0.06	0.40
Teva Pharmaceutical Industries Limited	0.26	0.96	2.09	0.35

31 more Peers available

Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.

Akari Therapeutics Plc's Revenue and Income Growth vs Peers

Quarterly revenue and net income growth, year over year and quarter over quarter

Company	Period	Revenue Y/Y	Revenue Q/Q	Income Y/Y	Income Q/Q
Akari Therapeutics Plc	Q1 2026	-	-	-	-
Abbvie Inc	Q3 2026	+10.3 %	+2.4 %	+2,143.6 %	+16.6 %
Amgen Inc	Q3 2026	+8.5 %	+3.1 %	+20.1 %	+62.7 %
Bristol myers Squibb Company	Q3 2026	+6.9 %	+0.7 %	-1.5 %	-34.8 %
Regeneron Pharmaceuticals Inc	Q3 2026	+36.3 %	+19.2 %	+33.5 %	+50.3 %
Teva Pharmaceutical Industries Limited	Q3 2026	-1.9 %	+6.1 %	-46.3 %	-
PEERS TOTAL		+11.1 %	+4.6 %	+69.4 %	+17.3 %

31 more Peers available

Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.

Akari Therapeutics Plc's Peers' Costs of Sales and Capital Expenditures

Context for revenue growth: peer costs and capex, year over year and quarter over quarter

Company	Period	Costs Y/Y	Costs Q/Q	Capex Y/Y	Capex Q/Q
Akari Therapeutics Plc	Q1 2026	-	-	-	-
Abbvie Inc	Q3 2026	-19.2 %	-0.1 %	-21.0 %	-6.5 %
Amgen Inc	Q3 2026	-9.5 %	-0.8 %	+34.6 %	+14.4 %
Bristol myers Squibb Company	Q3 2026	+20.7 %	+11.3 %	+7.5 %	+12.8 %
Regeneron Pharmaceuticals Inc	Q3 2026	+104.1 %	-0.5 %	+49.1 %	+25.0 %
Teva Pharmaceutical Industries Limited	Q3 2026	-10.2 %	-1.7 %	+200.0 %	+14.3 %

31 more Peers available

Akari Therapeutics Plc's Returns and Turnover vs Peers

ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover

Company	ROA	ROI	ROE	Receivables Turnover	Inventory Turnover
Akari Therapeutics Plc	-	-	-	-	-
Abbvie Inc	7.48%	12.87%	-	5.04	3.40
Amgen Inc	10.02%	13.64%	85.59%	3.96	1.81
Bristol myers Squibb Company	10.47%	13.59%	43.83%	4.77	5.65
Regeneron Pharmaceuticals Inc	11.50%	13.00%	15.07%	2.64	0.60
Teva Pharmaceutical Industries Limited	1.26%	1.96%	6.37%	3.89	3.16

31 more Peers available

ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).

Akari Therapeutics Plc's Valuation vs Peers

P/E, price to sales, PEG, price to cash flow and price to book

Company	P/E	Price / Sales	PEG	P/CF	Price / Book
Akari Therapeutics Plc	-	-	-	4,756,665.32	61,525.71
Abbvie Inc	50.77	7.92	0.35	101.59	-
Amgen Inc	27.14	6.57	0.47	68.25	17.81
Bristol myers Squibb Company	13.94	2.58	0.20	-	5.52
Regeneron Pharmaceuticals Inc	21.22	6.00	1.38	87.45	3.02
Teva Pharmaceutical Industries Limited	57.92	3.65	-	68.85	6.41
PEERS AVERAGE	61.83	9.72		288.61	20.42

31 more Peers available

P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.